- United States
- /
- Software
- /
- NasdaqGS:CVLT
Is Commvault Systems (CVLT) Fully Valued Following Its Minutes To Recovery Launch?
Commvault Systems (CVLT) is drawing fresh attention after launching Minutes to Recovery, a live cyber resilience simulation that puts security teams through AI driven attack, defense, and recovery scenarios.
See our latest analysis for Commvault Systems.
Commvault Systems’ Minutes to Recovery launch comes after a strong run in the stock, with a 30 day share price return of 13.67% and a 90 day share price return of 54.13%. The 1 year total shareholder return is down 14.10%, but the 3 year total shareholder return is 96.01% and the 5 year total shareholder return is 79.91%, pointing to solid longer term compounding despite recent volatility.
If this kind of AI driven security story has your attention, it could be a good moment to see what else is moving in the space through 62 profitable AI stocks that aren't just burning cash
Bulls see Commvault Systems’ AI driven cyber resilience push and recent share price strength as the start of a re rating, while bears see optimism already reflected. Which case looks closer to fair value when you run the numbers?
Most Popular Narrative: 9.3% Overvalued
Commvault Systems closed at $147.81 compared with a most widely followed fair value estimate of $135.20, which frames the current debate around how much future earnings power is already priced in.
Surging demand for enterprise data protection and recovery fueled by accelerating cyber threats, with Commvault's enhanced cyber resilience platform (including Cleanroom Recovery, Air Gap Protect, and the upcoming Satori Cyber acquisition) driving new customer adoption and increased wallet share, likely supporting sustained double-digit revenue and ARR growth.
Want to see what sits behind that confidence in Commvault Systems? The narrative leans heavily on recurring revenue, richer margins, and a future earnings profile that assumes much stronger profitability than today.
Result: Fair Value of $135.20 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Commvault Systems' reliance on large, lumpy term software deals, along with the ongoing shift toward subscription and SaaS revenue, introduces earnings and margin uncertainty.
Find out about the key risks to this Commvault Systems narrative.
Another View: Commvault Systems Through a Cash Flow Lens
The earlier fair value of $135.20 came from an earnings based approach, yet our DCF model points to a future cash flow value of $154.45, with Commvault Systems trading around $147.81. When earnings and cash flow send different signals like this, which one do you put more weight on?
For a closer look at how those cash flow assumptions stack up against the earnings narrative, it is worth going through the full workings behind the SWS DCF model: Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Commvault Systems for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With Commvault Systems attracting both confidence and caution from investors, do not wait for consensus to form before checking the detailed risk and reward breakdown through 2 key rewards and 2 important warning signs
Looking for more investment ideas beyond Commvault Systems?
If Commvault Systems has sharpened your focus, do not stop here. Broaden your watchlist with other clear setups using targeted screeners powered by the same data engine.
- Spot potential value opportunities early by scanning companies that combine quality fundamentals with attractive pricing through 47 high quality undervalued stocks.
- Strengthen the defensive side of your portfolio by filtering for resilient businesses using 82 resilient stocks with low risk scores.
- Hunt for lesser known opportunities with solid metrics by checking the screener containing 20 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NasdaqGS:CVLT
Commvault Systems
Provides cyber resiliency solutions for enterprises to protect, secure, and recover data, applications, and identity system.
Excellent balance sheet with moderate growth potential.
Similar Companies
Market Insights
Weekly Picks

The U.S. Government Is Desperate for This Metal. This Tiny Miner Has It -- Its Closest Peer Is Already Worth Double.
PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback
From $5M to $2B: Why the 2024 Crash Was the Best Buying Opportunity in Consumer Stocks
High-quality global services company facing an AI-driven valuation reset.
Recently Updated Narratives

burns cash despite four approved drugs, trapped by structural inefficiencies and gene-therapy scaling hurdles that thin safety margins.

Faces a brutal commercial dogfight against Pfizer’s entrenched monopoly and Alnylam’s silencers, compressing its safety margins

overprices legal wins and pipeline, ignoring fierce anti-FcRn competition, cash redeployment drag, and holding discounts.
Popular Narratives

Mastercard: The Best Dividend Stock You're Ignoring

The Wafer Giant Threatening NVIDIA's GPU Hegemony
PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback
Trending Discussion
An investment case is not about loving the product. Its about price vs reality.
